AU2022205713A1 - Thienyl and cycloalkyl aminopyrimidine compounds as inhibitors of nuak kinases, compositions and uses thereof - Google Patents

Thienyl and cycloalkyl aminopyrimidine compounds as inhibitors of nuak kinases, compositions and uses thereof Download PDF

Info

Publication number
AU2022205713A1
AU2022205713A1 AU2022205713A AU2022205713A AU2022205713A1 AU 2022205713 A1 AU2022205713 A1 AU 2022205713A1 AU 2022205713 A AU2022205713 A AU 2022205713A AU 2022205713 A AU2022205713 A AU 2022205713A AU 2022205713 A1 AU2022205713 A1 AU 2022205713A1
Authority
AU
Australia
Prior art keywords
alkyl
haloalkyl
heterocycloalkyl
cycloalkyl
halo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2022205713A
Other languages
English (en)
Other versions
AU2022205713A9 (en
Inventor
Rima AL-AWAR
Liliana Attisano
Methvin Isaac
Yong Liu
David Smil
David UEHLING
Jeff Wrana
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Toronto
Ontario Institute for Cancer Research
Sinai Health System
Original Assignee
University of Toronto
Ontario Institute for Cancer Research
Sinai Health System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Toronto, Ontario Institute for Cancer Research, Sinai Health System filed Critical University of Toronto
Publication of AU2022205713A1 publication Critical patent/AU2022205713A1/en
Publication of AU2022205713A9 publication Critical patent/AU2022205713A9/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2022205713A 2021-01-07 2022-01-07 Thienyl and cycloalkyl aminopyrimidine compounds as inhibitors of nuak kinases, compositions and uses thereof Abandoned AU2022205713A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163134739P 2021-01-07 2021-01-07
US63/134,739 2021-01-07
PCT/CA2022/050014 WO2022147620A1 (en) 2021-01-07 2022-01-07 Thienyl and cycloalkyl aminopyrimidine compounds as inhibitors of nuak kinases, compositions and uses thereof

Publications (2)

Publication Number Publication Date
AU2022205713A1 true AU2022205713A1 (en) 2023-07-27
AU2022205713A9 AU2022205713A9 (en) 2025-03-06

Family

ID=82356983

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022205713A Abandoned AU2022205713A1 (en) 2021-01-07 2022-01-07 Thienyl and cycloalkyl aminopyrimidine compounds as inhibitors of nuak kinases, compositions and uses thereof

Country Status (7)

Country Link
US (1) US20240025887A1 (https=)
EP (1) EP4274829A4 (https=)
JP (1) JP2024502174A (https=)
CN (1) CN116981664A (https=)
AU (1) AU2022205713A1 (https=)
CA (1) CA3204383A1 (https=)
WO (1) WO2022147620A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116903591B (zh) * 2023-07-13 2025-08-26 特科罗生物科技(成都)有限公司 一种嘧啶胺类nuak抑制剂及其制备方法和用途
CN116903592B (zh) * 2023-07-13 2025-08-01 特科罗生物科技(成都)有限公司 一种嘧啶胺类nuak抑制剂及其制备方法和用途
CN116947764B9 (zh) * 2023-07-13 2025-07-25 特科罗生物科技(成都)有限公司 一种嘧啶胺类nuak抑制剂及其制备方法和用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7754714B2 (en) * 2004-05-18 2010-07-13 Rigel Pharmaceuticals, Inc. Cycloalkyl substituted pyrimidinediamine compounds and their uses
EP1883302A4 (en) * 2005-05-03 2009-05-20 Rigel Pharmaceuticals Inc JAK KINASE HEMMER AND ITS USE
CA2634646C (en) * 2005-12-21 2012-04-10 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
CA2648170A1 (en) * 2006-04-10 2007-10-18 Boehringer Ingelheim International Gmbh 2, 4-diaminopyrimidine derivatives and their use for the treatment of cancer
ES2555803T3 (es) * 2006-10-23 2016-01-08 Cephalon, Inc. Fusión de derivados bicíclicos 2,4-diaminopirimidina como utilizar inhibidores ALK y c-Met
WO2008077885A2 (en) * 2006-12-22 2008-07-03 Boehringer Ingelheim International Gmbh 2- [(phenylamino) -pyrimidin-4ylamin0] -cyclopentane carboxamide derivatives and related compounds as inhibitors of kinases of the cell cycle for the treatment of cancer
EA017252B1 (ru) * 2007-08-28 2012-11-30 Айрм Ллк Производные 2-бифениламино-4-аминопиримидина в качестве ингибиторов киназ
MX353308B (es) * 2008-05-21 2018-01-08 Ariad Pharma Inc Derivados fosforosos como inhibidores de cinasa.
WO2012051587A1 (en) * 2010-10-14 2012-04-19 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in egfr-driven cancers
CN110724137B (zh) * 2019-11-13 2021-03-30 广东工业大学 一种噻吩类衍生物及其制备方法与应用

Also Published As

Publication number Publication date
JP2024502174A (ja) 2024-01-17
WO2022147620A1 (en) 2022-07-14
EP4274829A1 (en) 2023-11-15
US20240025887A1 (en) 2024-01-25
CN116981664A (zh) 2023-10-31
AU2022205713A9 (en) 2025-03-06
CA3204383A1 (en) 2022-07-14
EP4274829A4 (en) 2024-12-11

Similar Documents

Publication Publication Date Title
JP7553450B2 (ja) ユビキチン特異的プロテアーゼ１を阻害するための組成物
JP6441861B2 (ja) Ｆａｋ阻害剤としてのピリミジン誘導体
AU2008289037B2 (en) 5- (4- (haloalkoxy) phenyl) pyrimidine-2-amine compounds and compositions as kinase inhibitors
AU2022205713A9 (en) Thienyl and cycloalkyl aminopyrimidine compounds as inhibitors of nuak kinases, compositions and uses thereof
US20240092763A1 (en) Isoindolinone aminopyrimidine compounds as inhibitors of nuak kinases, compositions and uses thereof
KR101335746B1 (ko) 이치환된 프탈라진 헷지호그 경로 길항제
CA3124952A1 (en) Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer
TWI572593B (zh) 四氫喹唑啉酮衍生物
CA3073977A1 (en) Inhibitors of wdr5 protein-protein binding
US11192880B2 (en) Quinolone compounds as inhibitors of the BCL6 BTB domain protein-protein interaction and/or as BCL6 degraders
WO2016011979A1 (zh) 2，4-二取代7H-吡咯并[2，3-d]嘧啶衍生物、其制法与医药上的用途
WO2025108479A1 (en) Compounds for degradation or inhibition of kras mutant proteins and uses thereof
WO2019158025A1 (zh) 一种三氮唑并嘧啶衍生化合物、包含其的药物组合物及其用途
WO2020125759A1 (zh) 作为wnt信号通路抑制剂的化合物及其医学应用
AU2016356884A1 (en) Novel compounds as inhibitors of dna methyltransferases
JP2022518723A (ja) ピロロピリジン誘導体およびタンパク質キナーゼ関連疾患の予防または治療での使用のためのその用途
JP2012509265A (ja) 四置換ピリダジンヘッジホッグ経路アンタゴニスト
TWI464170B (zh) ５-酮基-５，８-二氫吡啶并［２，３-ｄ］嘧啶衍生物，其製備及其治療用途
CN104470922B (zh) 药物活性化合物
WO2005049577A1 (en) 1-amino-isoquinoline derivatives for the treatment of diseases associated with inappropriate alk5
CN111349093A (zh) 5,6-双环化合物作为wnt信号通路抑制剂及其医学应用
WO2012121168A1 (ja) キナーゼ阻害剤
US20260015328A1 (en) Atm kinase inhibitors
CN114805375B (zh) 一种n-苯基烷氧基二苯并吖庚因类化合物、其制备方法及医药用途
CN120518582A (zh) 一类并环结构取代的新型cdk12/13共价抑制剂或其药物组合物和应用

Legal Events

Date Code Title Description
SREP Specification republished
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period